2006
Multicenter Open-label Extension Trial of Long-term Treatment with Gefitinib (IRESSA®)
Nakagawa K, Ranson M, Yano S, Tamura T, Saka H, Imamura F, Yokoyama A, Matsui K, Jiang H, Herbst R. Multicenter Open-label Extension Trial of Long-term Treatment with Gefitinib (IRESSA®). Haigan 2006, 46: 345. DOI: 10.2482/haigan.46.345.Peer-Reviewed Original ResearchProgression-free survivalLong-term treatmentNew safety issuesExtension trialOpen-label extension trialSkin-related adverse eventsMedian overall survivalMajority of patientsLong-term safetyGefitinib monotherapyAdvanced NSCLCAdverse eventsOverall survivalParent trialClinical benefitGefitinib treatmentSafety profileClinical trialsClinical studiesPatientsGefitinibIdeal 1TrialsSafety issuesSurvival
2003
Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management
Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management. Clinical Lung Cancer 2003, 4: 366-369. PMID: 14599302, DOI: 10.3816/clc.2003.n.016.Peer-Reviewed Original ResearchDermatologic effectsGefitinib treatmentClinical trialsDry skinSide effectsFrequent drug-related adverse effectsDrug-related allergic reactionsRecent phase II trialDrug-related adverse effectsAdverse effectsDermatologic adverse effectsPhase II trialDermatologic side effectsCell lung cancerNumerous clinical trialsSimilar side effectsVariety of treatmentsMechanism of actionAcneiform rashTopical clindamycinAdvanced NSCLCEpidermal growth factor receptor tyrosine kinaseII trialMost patientsGefitinib therapy